Latest pharma updates on Gene Therapy

FDA Approves Novartis Gene Therapy Itvisma for Spinal Muscular Atrophy (SMA)

The U.S. FDA has granted Novartis' gene therapy Itvisma approval for the treatment of spinal muscular atrophy (SMA)...

Read Full Story

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.